NCT07577596RecruitingPhase 4
Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure
Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine. Furosemide is a commonly used water-removing medicine that is given into a vein to treat fluid overload. It can be given in different ways. One way is as a continuous infusion, where the medicine is given slowly over time through a pump. Another way is as repeated injections given several times a day. It is not known whether one of these ways is better than the other for removing excess fluid in people with acute heart failure. The purpose of this study is to compare two ways of giving furosemide into a vein: Continuous infusion started with an initial extra dose, and bolus injections given three times a day. About 436 adults admitted to hospitals in Denmark with acute heart failure and fluid overload will take part. Participants will be randomly assigned to one of the two treatment groups. This means that chance will decide which treatment method each participant receives. The main thing the researchers will measure is how much body weight participants lose about 3 days after randomization. Weight loss is used as a measure of how much excess fluid has been removed.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 436 (estimated)
- First submitted
- 28 Apr 2026
- Start date
- 30 Jun 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- University of Aarhus
- Diseases
- Heart failure
- NCT number
- NCT07577596
- EU CT number
- 2025-523589-26-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 436
- From 30 Jun 2026 to the primary completion date, 1 Sept 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient requiring treatment with inotropes or vasopressors
- Current or planned use of renal replacement therapy or ultrafiltration
- Patient with a renal transplant
Other illness
- Allergy to furosemide and its components
Lab values
- Severe hypokalaemia, defined as potassium less than 2.5 mmol/L, or severe hyponatremia, defined as sodium less than 125 mmol/L
Other
- Shock
- Patients who are pregnant or breastfeeding
Who the study is looking for
- Clinical diagnosis of acute heart failure with volume overload
- At least 1 sign of volume overload
- Anticipated intravenous furosemide treatment for at least 3 days
- Age 18 years or older
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Region Syddanmark Coordinator of this site? Confirm its status | Aabenraa | Denmark | Recruiting |
| Region Nordjylland Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
| Region Midtjylland Coordinator of this site? Confirm its status | Aarhus N | Denmark | Recruiting |
| Region Midtjylland Coordinator of this site? Confirm its status | Herning | Denmark | Recruiting |
| Region Midtjylland Coordinator of this site? Confirm its status | Horsens | Denmark | Recruiting |
| Region Midtjylland Coordinator of this site? Confirm its status | Randers Noe | Denmark | Recruiting |
| Region Syddanmark Coordinator of this site? Confirm its status | Vejle | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.